PACB - LONG

At the upcoming TD Cowen 44th Annual Health Care Conference and Barclays 26th Annual Global Healthcare Conference, PacBio is expected to present corporate updates, including recent achievements and product advancements, financial performance, and strategic outlook. The company may also discuss industry trends, how its sequencing solutions are positioned within the genomics market, and plans for addressing future demands. These presentations aim to reinforce investor confidence by highlighting PacBio's strengths, strategic directions, and potential in the rapidly evolving genomics industry, complemented by opportunities for direct engagement with investors and industry stakeholders through Q&A sessions and networking.

Macro support here, Nice uptick in Volume.

Good luck traders.

Trade active:

Averaging down here. 4.20 area. Watching for PR.

Trade active:

Insider Purchasing: Director David Meline's recent purchase of 40,000 shares in Pacific Biosciences of California Inc (PACB) signals strong insider confidence, contrasting with the broader trend of more insider selling than buying over the past year. Despite the stock being labeled a Possible Value Trap based on its price-to-GF-Value ratio, Meline's investment could indicate a belief in the company's undervaluation and growth potential. This insider activity, particularly when it diverges from the majority's selling pattern, might influence market perceptions and investor interest, suggesting Meline sees upcoming positive developments or an attractive entry point that the market has yet to fully appreciate.

The spike in volume over the past few days, and the spike in volume on the 30 minute, the effect it had on the price leaving us with a hammer, suggesting aggressive buying. We are heading at the bottom end of a liquidity pocket, so i wouldn't expect us to trade too much higher until we get some news going here.

Continuing to accumulate. Watching....